Time course, magnitude, and consistency platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention

American Journal of Cardiology

Volumn 84, Issue 4, 1999, Pages 391-395

  Kereiakes, Dean J ^a   Broderick, Thomas M ^c   Roth, Eli M ^a   Whang, David ^c   Shimshak, Thomas ^a   Runyon, John Paul ^c   Hattemer, Charles ^c   Schneider, John ^c   Lacock, Pam ^b   Mueller, Michele ^a   Abbottsmith, Charles W ^c  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b Health Alliance Laboratory Service   (United States)

^c Ohio Heart and Vascular Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; TICLOPIDINE; TIROFIBAN;

ARTICLE; ASSAY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; FEMALE; FUNCTION TEST; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; MALE; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 0033566637     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00321-5     Document Type: Article

References (25)

1. Coller B.S. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation. 92:1995;2373-2380.
2. Ezratty A.M., Loscalzo J. New approaches to antiplatelet therapy. Blood Coagul Fibrinol. 2:1991;317-327.
3. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-96l.
4. Platelet glycoprotein IIb/IIIa receptor blockade in low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
5. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II . Lancet. 349:1997;1422-1428.
6. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
7. Coller B.S., Lang D., Scudder L.E. A rapid and simple platelet function assay to assess GP IIb/IIIa receptor blockade. Circulation. 95:1997;860-867.
8. Mascelli M.A., Worley S., Veriabo N.J., Lance E.T., Mack S., Schaible T., Weisman H.F., Jordan R.E. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti GP IIb/IIIa therapy. Circulation. 96:1997;3860-3866.
9. Smith J.W., Steinhubl S.R., Lincoff A.M., Coleman J., Li T., Hillman R.S., Coller B.S. The rapid platelet function assay (RPFA) an automated and quantitative cartridge-based method . Circulation. 99:1999;620-625.
10. Kereiakes D.J., Mueller M., Howard W., Lacock P., Anderson L.C., Broderick T.M., Roth E.M., Abbottsmith M.D. Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J Thromb Thrombol. 7:1999;265-275.
11. Levine P.H. The effect of thrombocytopenia on determination of platelet aggregation. Am J Clin Pathol. 65:1976;79-82.
12. Trip M.D., Gats V.M., van Capelle F.J.L., Vreeken J. Platelet hyper-reactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 322:1990;1549-1554.
13. Coller B.S. Platelet aggregation by ADP, collagen and ristocetin a critical review of methodology and analysis . Schmidt R.M. CRC Handbook Series in Clinical Laboratory Science. 1979;381 CRC Press, Boca Raton, FL.
14. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 338:1998;1488-1497.
15. Kereiakes D.J., Kleiman N.S., Ambrose J., Cohen M., Rodriquez S., Palabrica T., Herrmann H.C., Sutton J.M., Weaver W.D., McKee D.B., Fitzpatrick V., Sav F.L. Randomized, double-blind placebo controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing percutaneous coronary angioplasty. J Am Coll Cardiol. 27:1996;536-542.
16. Tcheng J.E., Ellis S.G., George B.S., Kereiakes D.J., Kleiman N.S., Talley J.D., Wang A.L., Weisman H.F., Califf R.M., Topol E.J. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antibody Fab-7E3 in high risk coronary angioplasty. Circulation. 90:1994;1756-1764.
17. Gilchrist I.C., Thel M.C., Joseph D., Zimmerman H.E., Jennings L.K., Kleiman N.S., Kereiakes D.J., Talley J.D., O'Brien M.A., Lorenz T.J., Tcheng J.E. Enhanced platelet IIb/IIIa inhibition with eptifibatide via high dose double bolus dosing final results of the PRIDE study . (abstr) Circulation. 98:(suppl I):1998;I-844.
18. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 339:1998;436-443.
19. Gold H.K., Gimple L., Yasuda T., Leinbach R., Werner W., Holt R., Jordan R., Berger H., Collen D., Coller B.S. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest. 86:1990;651-659.
20. Coller B.S., Scudder L.E., Beer J., Gold H.K., Foltz J.D., Cabagnaro J., Jordan R., Wagner C., Iuliucci J., Knight D., Ghraymab J., Smith C., Weisman H., Berger H. Monoclonal antibodies to platelet GP IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci. 614:1991;193-213.
21. Wencel-Drake J., Plow E., Zimmerman T., Painter R., Ginsberg M. Immuno-fluorescent localization of adhesive glycoprotein in resting and thrombin-stimulated platelet. Am J Pathol. 115:1984;156-164.
22. Kleiman N.S., Raizner A.E., Jordan R., Wang A.L., Norton D., Mace K.F., Joshi A., Collier B.S., Weisman H.F. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab implications for inhibition of the internal pool of GP IIb/IIIa receptors . J Am Coll Cardiol. 26:1995;1665-1671.
23. Valles J., Santos M.T., Aznar J., Osa A., Lago A., Cosin J., Sanchez E., Broekman M.J., Marcus A.J. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity . Circulation. 97:1998;350-355.
24. 2+ on GP IIb/IIIa interactions with integrilin. Circulation. 96:1997;1488-1494.
25. Storey R.F., Wilcox R.G., Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation. 98:1998;1616-1621.